Clinical Data Revolution rockets on strong pancreatic cancer data PharmaphorumRevolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.Clinical DataOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib. Clinical DataOncologyRead full story Post navigation Previous: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priorityNext: Novo Nordisk and OpenAI forge alliance to drive speedy drug development Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
